Search research articles
Contact Us
Filters
Showing results (201-210 of 211) with videos related to
Page
of 22
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
The New England Journal of Medicine
|
September 29, 2015
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
Hossein Borghaei, Luis Paz-Ares, Leora Horn, et al.
Cancer Discovery
|
September 14, 2023
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
Tina Cascone, Gozde Kar, Jonathan D Spicer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2021
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer
Hossein Borghaei, Scott Gettinger, Everett E Vokes, et al.
The New England Journal of Medicine
|
October 4, 2018
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott J Antonia, Augusto Villegas, Davey Daniel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2015
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N Gettinger, Leora Horn, Leena Gandhi, et al.
The New England Journal of Medicine
|
June 5, 2012
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 27, 2019
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
Taofeek K Owonikoko, Huifeng Niu, Kristiaan Nackaerts, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 6, 2017
Scientific Advances in Thoracic Oncology 2016
Ross A Soo, Emily C A Stone, K Michael Cummings, et al.
Cancer Research
|
August 29, 2025
TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy
Leanne G Ahronian, Soumyadip Sahu, Minjie Zhang, et al.
Page
of 22
Search research articles
Search
Showing results (201-210 of 211) with videos related to
Sort By:
Page
of 22
Proceedings of the National Academy of Sciences of the United States of America
|
October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
The New England Journal of Medicine
|
September 29, 2015
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
Hossein Borghaei, Luis Paz-Ares, Leora Horn, et al.
Cancer Discovery
|
September 14, 2023
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
Tina Cascone, Gozde Kar, Jonathan D Spicer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2021
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer
Hossein Borghaei, Scott Gettinger, Everett E Vokes, et al.
The New England Journal of Medicine
|
October 4, 2018
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott J Antonia, Augusto Villegas, Davey Daniel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2015
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N Gettinger, Leora Horn, Leena Gandhi, et al.
The New England Journal of Medicine
|
June 5, 2012
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 27, 2019
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
Taofeek K Owonikoko, Huifeng Niu, Kristiaan Nackaerts, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 6, 2017
Scientific Advances in Thoracic Oncology 2016
Ross A Soo, Emily C A Stone, K Michael Cummings, et al.
Cancer Research
|
August 29, 2025
TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy
Leanne G Ahronian, Soumyadip Sahu, Minjie Zhang, et al.
Page
of 22